gabapentin has been researched along with Breast Cancer in 42 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preoperative administration of gabapentin reduced intraoperative propofol requirements and postoperative analgesic consumption in breast cancer patients undergoing total mastectomy." | 9.17 | Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013) |
| "Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety." | 9.16 | A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012) |
| "Breast cancer survivors prefer venlafaxine over gabapentin for treating hot flashes." | 9.14 | Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. ( Bordeleau, L; Ennis, M; Goodwin, PJ; Haq, R; Jugovic, O; Loprinzi, CL; Pritchard, KI; Warr, D, 2010) |
| "To assess the efficacy and the tolerability of gabapentin 900 mg/day compared to vitamin E for the control of vasomotor symptoms in 115 women with breast cancer." | 9.14 | Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009) |
| "In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks." | 9.11 | Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004) |
| "In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin." | 9.10 | Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. ( Griggs, J; Guttuso, T; Roscoe, J, 2003) |
| "The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery." | 8.98 | The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018) |
| " We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain." | 8.95 | Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017) |
| "Hot flashes are a common and debilitating symptom among survivors of breast cancer." | 6.80 | Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. ( Bowman, MA; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Xie, SX, 2015) |
| "Gabapentin is an anticonvulsant that the United States Food and Drug Administration approved as an adjunct therapy for partial seizures and postherpetic neuralgia." | 6.45 | Use of gabapentin in patients experiencing hot flashes. ( Brown, JN; Wright, BR, 2009) |
| " Women with breast cancer were randomized into two groups of paclitaxel chemotherapy with gabapentin 300 mg/three times a day orally or placebo for 2 weeks started at day 1 of each paclitaxel cycle." | 5.30 | Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. ( Aghili, M; Akrami, S; Esmati, E; Ghalehtaki, R; Kalaghchi, B; Mousavi, N; Sotoudeh, S; Zare, M, 2019) |
| "Preoperative administration of gabapentin reduced intraoperative propofol requirements and postoperative analgesic consumption in breast cancer patients undergoing total mastectomy." | 5.17 | Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery. ( Bala, I; Bharti, N; Narayan, V; Singh, G, 2013) |
| "Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety." | 5.16 | A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. ( Amos, E; Heckler, C; Jacobs, A; Kirshner, JJ; Lavigne, JE; Lord, R; Mathews, JL; Morrow, GR; Mustian, K; Palesh, O, 2012) |
| "Breast cancer survivors prefer venlafaxine over gabapentin for treating hot flashes." | 5.14 | Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. ( Bordeleau, L; Ennis, M; Goodwin, PJ; Haq, R; Jugovic, O; Loprinzi, CL; Pritchard, KI; Warr, D, 2010) |
| "To assess the efficacy and the tolerability of gabapentin 900 mg/day compared to vitamin E for the control of vasomotor symptoms in 115 women with breast cancer." | 5.14 | Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. ( Biglia, N; Bounous, V; Marenco, D; Moggio, G; Peano, E; Ponzone, R; Sgandurra, P; Sismondi, P; Tomasi Cont, N, 2009) |
| "In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks." | 5.11 | Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. ( Griggs, JJ; Guttuso, TJ; Morrow, GR; Pandya, KJ; Roscoe, JA; Rosenblatt, JD; Sahasrabudhe, DM; Thummala, AR, 2004) |
| " Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos." | 5.11 | Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005) |
| "In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin." | 5.10 | Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. ( Griggs, J; Guttuso, T; Roscoe, J, 2003) |
| "The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery." | 4.98 | The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018) |
| " We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain." | 4.95 | Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017) |
| "Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer." | 4.86 | Non-hormonal interventions for hot flushes in women with a history of breast cancer. ( Capurro, D; Corbalán, J; Letelier, LM; Moreno, G; Pantoja, T; Rada, G; Vera, C, 2010) |
| "Centrally active agents (eg, venlafaxine, paroxetine, gabapentin) are regarded as the most promising nonhormonal treatments for hot flashes in breast cancer survivors." | 4.84 | Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. ( Bordeleau, L; Goodwin, P; Loprinzi, C; Pritchard, K, 2007) |
| "To report a case of recurrent hot flashes unresponsive to gabapentin in a postmenopausal patient with a positive family history of breast cancer." | 3.81 | Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer. ( Lake, J; Leong, C, 2015) |
| "A new study published in the Journal of Clinical Oncology has ascertained the efficacy of selective serotonin-reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors and gabapentin to decrease menopausal hot flashes." | 3.76 | Therapy: nonhormonal treatment of hot flashes-a viable alternative? ( Nachtigall, LE, 2010) |
| "116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron." | 3.74 | [Multimodal treatment of pain and nausea in breast cancer surgery]. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008) |
| " We present a case of asterixis as a cause of falls and near falls in a patient with metastatic breast cancer and normal mental status who was receiving gabapentin." | 3.73 | Asterixis related to gabapentin as a cause of falls. ( Babiy, M; Hand, M; Herklotz, M; Stubblefield, MD, 2005) |
| "Hot flashes are a common and debilitating symptom among survivors of breast cancer." | 2.80 | Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. ( Bowman, MA; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Xie, SX, 2015) |
| "Of 200 consecutive breast cancer patients, 191 received the full package." | 2.75 | Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2010) |
| "A third of female patients with cancer report dissatisfaction with the quality and length of physician-patient discussions about reproductive health, including menopause." | 2.58 | Managing menopausal symptoms after cancer: an evidence-based approach for primary care. ( Hickey, M; Marino, JL; McNamara, HC, 2018) |
| "Gabapentin is an anticonvulsant that the United States Food and Drug Administration approved as an adjunct therapy for partial seizures and postherpetic neuralgia." | 2.45 | Use of gabapentin in patients experiencing hot flashes. ( Brown, JN; Wright, BR, 2009) |
| "In men with prostate cancer, hot flushes occur after surgical or medical castration." | 2.43 | Treatment of hot flushes in breast and prostate cancer. ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005) |
| "5 mg/d, are reasonable initial dosages, and if symptoms do not improve within a week or two, the dosage can be doubled." | 2.42 | Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004) |
| "Menopausal symptoms following breast cancer can occur at an earlier age, be more severe and significantly influence a woman's overall wellbeing, in particular, sexual function, quality of life and adherence to treatment." | 1.48 | The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview. ( Baber, R; Phua, C, 2018) |
| "Women affected by breast cancer (BC) will often go through menopause at an earlier age and display more frequent and severe symptoms than women who have a natural menopause." | 1.40 | Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank. ( Ameye, L; Antoine, C; Paesmans, M; Rozenberg, S, 2014) |
| "Delirium is still one of the most common and distressing symptoms in palliative care patients." | 1.38 | Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012) |
| "Menopausal symptom management after breast cancer may be complex, and we present a novel model of care using a multidisciplinary approach." | 1.36 | The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care. ( Doherty, DA; Emery, LI; Gregson, J; Hickey, M; Saunders, CM, 2010) |
| "To describe isolated generalized polymyoclonus and the outcomes of etiologic evaluations at the time of diagnosis." | 1.34 | Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (35.71) | 29.6817 |
| 2010's | 24 (57.14) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Coraci, D | 1 |
| Giovannini, S | 1 |
| Loreti, C | 1 |
| Fusco, A | 1 |
| Padua, L | 1 |
| Kennedy, GT | 1 |
| Hill, CM | 1 |
| Huang, Y | 1 |
| So, A | 1 |
| Fosnot, J | 1 |
| Wu, L | 1 |
| Farrar, JT | 2 |
| Tchou, J | 1 |
| Shan, D | 1 |
| Zou, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Cai, Y | 1 |
| Zhang, J | 1 |
| Woyka, J | 1 |
| Cobin, RH | 1 |
| Goodman, NF | 1 |
| Rai, AS | 1 |
| Khan, JS | 1 |
| Dhaliwal, J | 1 |
| Busse, JW | 1 |
| Choi, S | 1 |
| Devereaux, PJ | 1 |
| Clarke, H | 1 |
| Marino, JL | 1 |
| McNamara, HC | 1 |
| Hickey, M | 2 |
| Phua, C | 1 |
| Baber, R | 1 |
| Jiang, Y | 1 |
| Li, J | 1 |
| Lin, H | 1 |
| Huang, Q | 1 |
| Wang, T | 1 |
| Zhang, S | 1 |
| Zhang, Q | 1 |
| Rong, Z | 1 |
| Xiong, J | 1 |
| da Cunha Leal, P | 1 |
| Rey Moura, EC | 1 |
| Jorge Dino Cossetti, R | 1 |
| Ramos do Nascimento, J | 1 |
| Portela Bogéa Serra, IC | 1 |
| de Paulo Ribeiro, B | 1 |
| Álvares Marques Vale, A | 1 |
| Silva de Azevedo Dos Santos, AP | 1 |
| Fernandes do Nascimento, FR | 1 |
| Kimiko Sakata, R | 1 |
| Aghili, M | 1 |
| Zare, M | 1 |
| Mousavi, N | 1 |
| Ghalehtaki, R | 1 |
| Sotoudeh, S | 1 |
| Kalaghchi, B | 1 |
| Akrami, S | 1 |
| Esmati, E | 1 |
| Bharti, N | 1 |
| Bala, I | 1 |
| Narayan, V | 1 |
| Singh, G | 1 |
| Antoine, C | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Rozenberg, S | 1 |
| Leong, C | 1 |
| Lake, J | 1 |
| Mao, JJ | 2 |
| Bowman, MA | 1 |
| Xie, SX | 2 |
| Bruner, D | 1 |
| DeMichele, A | 1 |
| Garland, SN | 1 |
| Li, Q | 1 |
| Seluzicki, C | 1 |
| Basal, C | 1 |
| Gärtner, R | 3 |
| Callesen, T | 3 |
| Kroman, N | 3 |
| Kehlet, H | 4 |
| Brown, JN | 1 |
| Wright, BR | 1 |
| Biglia, N | 1 |
| Sgandurra, P | 1 |
| Peano, E | 1 |
| Marenco, D | 1 |
| Moggio, G | 1 |
| Bounous, V | 1 |
| Tomasi Cont, N | 1 |
| Ponzone, R | 1 |
| Sismondi, P | 1 |
| Kontos, M | 1 |
| Agbaje, OF | 1 |
| Rymer, J | 1 |
| Fentiman, IS | 1 |
| Nachtigall, LE | 1 |
| Amr, YM | 1 |
| Yousef, AA | 1 |
| Emery, LI | 1 |
| Gregson, J | 1 |
| Doherty, DA | 1 |
| Saunders, CM | 1 |
| Rada, G | 1 |
| Capurro, D | 1 |
| Pantoja, T | 1 |
| Corbalán, J | 1 |
| Moreno, G | 1 |
| Letelier, LM | 1 |
| Vera, C | 1 |
| Bordeleau, L | 2 |
| Pritchard, KI | 1 |
| Loprinzi, CL | 2 |
| Ennis, M | 1 |
| Jugovic, O | 1 |
| Warr, D | 1 |
| Haq, R | 1 |
| Goodwin, PJ | 1 |
| Kierner, KA | 1 |
| Jagsch, C | 1 |
| Watzke, HH | 1 |
| Lavigne, JE | 1 |
| Heckler, C | 1 |
| Mathews, JL | 1 |
| Palesh, O | 1 |
| Kirshner, JJ | 1 |
| Lord, R | 1 |
| Jacobs, A | 1 |
| Amos, E | 1 |
| Morrow, GR | 2 |
| Mustian, K | 1 |
| Sarkissian, A | 1 |
| Neher, JO | 1 |
| Singh, R | 1 |
| St Anna, L | 1 |
| Lefkowits, CC | 1 |
| Arnold, RM | 1 |
| Fassoulaki, A | 2 |
| Patris, K | 1 |
| Sarantopoulos, C | 2 |
| Hogan, Q | 1 |
| Guttuso, T | 1 |
| Roscoe, J | 1 |
| Griggs, J | 1 |
| Pandya, KJ | 1 |
| Thummala, AR | 1 |
| Griggs, JJ | 1 |
| Rosenblatt, JD | 1 |
| Sahasrabudhe, DM | 1 |
| Guttuso, TJ | 1 |
| Roscoe, JA | 1 |
| Stearns, V | 1 |
| Hsu, C | 1 |
| Sliwa, JA | 1 |
| Babiy, M | 1 |
| Stubblefield, MD | 1 |
| Herklotz, M | 1 |
| Hand, M | 1 |
| Adelson, KB | 1 |
| Hershman, DL | 1 |
| Triga, A | 1 |
| Melemeni, A | 1 |
| Pritchard, K | 1 |
| Goodwin, P | 1 |
| Loprinzi, C | 1 |
| McKeon, A | 1 |
| Pittock, SJ | 1 |
| Glass, GA | 1 |
| Josephs, KA | 1 |
| Bower, JH | 1 |
| Lennon, VA | 1 |
| Ahlskog, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Connective Tissue Manipulation on Menopausal Symptoms[NCT05293860] | 58 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| "Preoperative Gabapentin and Its Effects on Postoperative Analgesia in Patients Undergoing Cosmetic Breast Surgery"[NCT05997355] | 100 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Early Acupuncture Treatment of Vasomotor Symptoms and Sleep Disorders in Breast Cancer Luteinising Hormone-releasing Hormone Analogues(LHRHa) Induced Menopause: AcuHOTFLASH Study[NCT05760222] | 90 participants (Anticipated) | Interventional | 2021-11-25 | Recruiting | |||
| Self-acupressure for Cancer-related Symptom Cluster of Insomnia, Depression, and Anxiety in Cancer Patients: a Feasibility Randomized Controlled Trial[NCT03823456] | 114 participants (Anticipated) | Interventional | 2018-12-04 | Recruiting | |||
| Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors[NCT01005108] | Phase 2 | 120 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain[NCT01619852] | 148 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial[NCT01904266] | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study[NCT04875559] | 236 participants (Actual) | Observational [Patient Registry] | 2021-04-19 | Completed | |||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology[NCT01403168] | 28 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Recruitment difficulties) | |||
| Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.[NCT00711529] | Phase 3 | 27 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
The participants development of chronic persistent pain 3 months after surgery as determined by character severity (yes/no). (NCT01619852)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Group L | 2 |
| .9% Normal Saline Placebo | 6 |
The amount of opioid analgesics consumed was converted to an equivalent dose of intravenous morphine. (NCT01619852)
Timeframe: 24 hours
| Intervention | equivalent dose of intravenous morphine (Median) |
|---|---|
| Group L | 34 |
| .9% Normal Saline Placebo | 39 |
Postoperative pain within the first 24 hours. Area under the numeric rating scale for pain versus time curve during the first 24 hours after surgery (score * hr). Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve during the first 24 hours ( score * hr). The pain scores were collected upon arrival to recovery area, 30 minutes, 1 hour and every 6 hours up to 24 hours following the procedure. Minimum score is 60, Maximum score is 170. A higher value indicates more pain. (NCT01619852)
Timeframe: 24 hours
| Intervention | score on a scale (Median) |
|---|---|
| Group L | 116 |
| .9% Normal Saline Placebo | 119 |
Quality of recovery (QoR-40 instrument) is a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Score range: 40 to 200. A score of 40 demonstrates poor recovery and a maximum score of 200 represents good recovery. The higher the score the better recovery after surgery. (NCT01619852)
Timeframe: 24 hours post operative
| Intervention | units on a scale (Median) |
|---|---|
| Lidocaine (Group L) | 158 |
| .9% Normal Saline Placebo | 169 |
The development of chronic pain 3 months after surgery determined by the Leads Assessment of Neuropathic Symptoms and Signs (LANSS) scale, a valid 7-item tool for identifying patients whose pain is dominated by neuropathic mechanisms. Each item is a binary response (yes or no) to the presence of symptoms (5 items) or clinical signs (2 items), range 0-24 points. A score ≥ 12, neuropathic mechanisms are likely to be contributing to the patient's pain. A score < 12 is unlikely to be contributing. McGill questionnaire (Sensory domain) - 11 descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe. The higher the score, greater the pain (range 0-33). McGill questionnaire (Motivational-affective) 4 affect descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe.The higher the score the greater the pain (range 0-12) Brief pain inventory - pain severity (0, no pain, 10 excruciating pain); Greater the score; greater the pain (range 0-10). (NCT01619852)
Timeframe: 3 months
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| S-LANNS | McGill Questionaire-Sensory Discrimation | McGill Questionaire-Motivational-affective | Brief Pain Inventory | |
| .9% Normal Saline Placebo | 3 | 3 | 0 | 1 |
| Group L | 3 | 4 | 0 | 1 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All nine women who initiated hypnotherapy treatment completed the survey at the end of 8 weeks. One woman in the gabapentin arm did not submit a survey at 8 weeks. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 26 |
| Gabapentin | 22 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten hot flash-related symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). Of 11 eligible women in the hypnotherapy arm, 2 never initiated treatment, and 3 did not complete the survey at this time point. Of the 14 eligible women in the gabapentin arm, 3 never initiated treatment, and 3 dropped out of the study before the 4 week time point. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 25.5 |
| Gabapentin | 21.5 |
The HFRDIS is a validated survey of 10 questions asking patients to rate ten symptoms on a scale of 0-10. The HFRDIS is a sum of the scores in each category, so that total score can range from 0 (no symptoms) to 100 (10 severe symptoms). These surveys were conducted at the time of enrollment (baseline), after four weeks of treatment, and at the conclusion of the study (8 weeks). All women who were randomized were included in the baseline analysis (with the exception of 2 women excluded from the hypnotherapy arm who were deemed ineligible after randomization). (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (HFRDIS) (Median) |
|---|---|
| Hypnotherapy | 58 |
| Gabapentin | 45.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Baseline
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 10 |
| Gabapentin | 7.5 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 4
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 6.5 |
| Gabapentin | 4 |
The patients kept daily hot flash diaries, including the total number of hot flashes they characterized as mild, moderate,severe and very severe. Hot flash severity scores were calculated by assigning one point to each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash and four points for each very severe hot flash. The hot flash severity score for a 24 hour period was the sum of these scores. The score was calculated for each day in the diary. For each subject, median scores were calculated for each week (7 day period) of participation. The median hot flash severity score for the first week was considered the baseline. The median hot flash severity score for the fourth week is considered the week 4 time point. The median hot flash severity score for the eighth week is considered the week 8 time point. The median result for the group was then calculated at each of the timepoints. (NCT00711529)
Timeframe: Week 8
| Intervention | units on a scale (severity score) (Median) |
|---|---|
| Hypnotherapy | 1.5 |
| Gabapentin | 5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). A total of 15 diaries were submitted (7 hypnotherapy, 8 gabapentin). One person in each arm stopped recording in her diary before the 4 week mark." (NCT00711529)
Timeframe: Week 4
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 4 |
| Gabapentin | 4 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). Of the 13 women randomized to the hypnotherapy arm, 2 women were ineligible and therefore not included in analysis. Two women were unable to initiate treatment and did not submit diaries. An additional two women completed treatment but lost their diaries, leaving 7 diaries for analysis at baseline. Of the 14 randomized to receive gabapentin, 6 dropped out of the study and did not submit diaries." (NCT00711529)
Timeframe: Baseline
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 5 |
| Gabapentin | 4.5 |
"Patients kept daily diaries of their hot flashes. The absolute number of hot flashes in a 24 hour period is number of daily hot flashes. The median number was calculated for each week of data. The median number of daily hot flashes for the first week (7 days) of participation is used as baseline. The median number of daily hot flashes for the fourth week (over 7 day interval) is reported for the week four time point. The median number of daily hot flashes for the eighth week (over 7 day interval) is reported for the week eight time point (study completion). One woman in the hypnotherapy arm and 3 women in the gabapentin arm stopped keeping their diary before the 8 week mark." (NCT00711529)
Timeframe: Week 8
| Intervention | daily hot flashes (Median) |
|---|---|
| Hypnotherapy | 1 |
| Gabapentin | 3 |
11 reviews available for gabapentin and Breast Cancer
| Article | Year |
|---|---|
Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcium Channel Blockers; Dizziness; Estrogen Rep | 2020 |
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2017 |
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2017 |
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2017 |
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2017 |
Managing menopausal symptoms after cancer: an evidence-based approach for primary care.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amenorrhea; Anti-Anxiety Agents; Breast Neoplasms; Canc | 2018 |
The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis.
Topics: Amines; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amino | 2018 |
Use of gabapentin in patients experiencing hot flashes.
Topics: Amines; Breast Neoplasms; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2009 |
What can be done about hot flushes after treatment for breast cancer?
Topics: Amines; Anesthetics, Local; Breast Neoplasms; Bupivacaine; Clonidine; Complementary Therapies; Cyclo | 2010 |
Non-hormonal interventions for hot flushes in women with a history of breast cancer.
Topics: Acupuncture Therapy; Amines; Breast Neoplasms; Clonidine; Cyclohexanecarboxylic Acids; Excitatory Am | 2010 |
Clinical Inquiry: Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?
Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Constipation; Cyclohexanecarboxylic Acids; Cyclohexan | 2012 |
Management of hot flashes in breast cancer survivors and men with prostate cancer.
Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Complementary Therapies; Contraceptives, Oral, Synthe | 2004 |
Treatment of hot flushes in breast and prostate cancer.
Topics: Amines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cimicifuga; Contraindications; Cyclohexan | 2005 |
Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.
Topics: Amines; Antidepressive Agents; Breast Neoplasms; Complementary Therapies; Cyclohexanecarboxylic Acid | 2007 |
13 trials available for gabapentin and Breast Cancer
| Article | Year |
|---|---|
Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Double-Blind Method; Female; Gabapentin; | 2019 |
Effect of gabapentin pretreatment on propofol consumption, hemodynamic variables, and postoperative pain relief in breast cancer surgery.
Topics: Adult; Amines; Analgesics; Anesthetics, Intravenous; Breast Neoplasms; Cyclohexanecarboxylic Acids; | 2013 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
Topics: Adult; Aged; Amines; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Electroa | 2015 |
Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial.
Topics: Acupuncture Therapy; Adult; Aged; Amines; Anti-Anxiety Agents; Breast Neoplasms; Cyclohexanecarboxyl | 2017 |
Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.
Topics: Adult; Aged; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2009 |
Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain.
Topics: Acute Disease; Adult; Amines; Analgesics; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic A | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.
Topics: Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Breast Neoplasms; Cross-Over | 2010 |
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.
Topics: Amines; Anti-Anxiety Agents; Anxiety; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapen | 2012 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer.
Topics: Acetates; Administration, Oral; Amines; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2003 |
Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.
Topics: Acetates; Administration, Oral; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabap | 2004 |
Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.
Topics: Acute Disease; Adult; Amines; Analgesia; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cycl | 2005 |
18 other studies available for gabapentin and Breast Cancer
| Article | Year |
|---|---|
Management of neuropathic pain: A graph theory-based presentation of literature review.
Topics: Breast Neoplasms; Gabapentin; Humans; Neuralgia; Paclitaxel | 2020 |
Enhanced recovery after surgery (ERAS) protocol reduces perioperative narcotic requirement and length of stay in patients undergoing mastectomy with implant-based reconstruction.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Breast Implantation; Breast Neoplasms; Dose-Response | 2020 |
Consensus statement for non-hormonal-based treatments for menopausal symptoms.
Topics: Amines; Anticonvulsants; Antihypertensive Agents; Behavior Therapy; Breast Neoplasms; Clonidine; Con | 2017 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Amines; Breast Neoplasms; Cardiovascular Dise | 2017 |
The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview.
Topics: Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2018 |
High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites.
Topics: Analgesics; Animals; Arginase; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Chemokine CCL2; Disease M | 2019 |
Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank.
Topics: Aged; Amines; Antidepressive Agents; Antineoplastic Agents; Aromatase Inhibitors; Belgium; Breast Ne | 2014 |
Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer.
Topics: Aged; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2015 |
[Postoperative inconveniences after breast cancer surgery].
Topics: Acetaminophen; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasms; Celecoxib; Cyc | 2008 |
[Multimodal treatment of pain and nausea in breast cancer surgery].
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasm | 2008 |
Therapy: nonhormonal treatment of hot flashes-a viable alternative?
Topics: Adrenergic Uptake Inhibitors; Amines; Antidepressive Agents; Breast Neoplasms; Contraindications; Cy | 2010 |
The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Amines; Anti-Anxiety Agents; Breast Neop | 2010 |
Reversible delirium in an advanced cancer patient.
Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No | 2012 |
Hot flashes in palliative care. Part 2 #262.
Topics: Amines; Analgesics; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clonidine; Cyclohexanecarboxy | 2013 |
Phantom breast pain as a source of functional loss.
Topics: Acetates; Activities of Daily Living; Amines; Anti-Anxiety Agents; Breast Neoplasms; Carcinoma in Si | 2004 |
Asterixis related to gabapentin as a cause of falls.
Topics: Accidental Falls; Aged; Amines; Analgesics; Breast Neoplasms; Cyclohexanecarboxylic Acids; Diagnosis | 2005 |
Perioperative analgesia to prevent chronic postmastectomy pain.
Topics: Amines; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2006 |
Whole-body tremulousness: isolated generalized polymyoclonus.
Topics: Adult; Aged; Amines; Anticonvulsants; Autoimmunity; Breast Neoplasms; Clonazepam; Cyclohexanecarboxy | 2007 |